VR can spot early symptoms of Alzheimer's: Study

Agencies
May 24, 2019

London, May 24: Virtual reality (VR) can identify early symptoms of Alzheimer's disease more accurately than 'gold standard' cognitive tests currently in use, a study claims.

Researchers at the University of Cambridge in the UK noted that brain contains a mental 'satnav' (satellite navigation) of where we are, where we have been, and how to find our way around.

A key component of this internal satnav is a region of the brain known as the entorhinal cortex.

This is one of the first regions to be damaged in Alzheimer's disease, which may explain why 'getting lost' is one of the first symptoms of the disease.

However, the pen-and-paper cognitive tests used in the clinic to diagnose the condition are unable to test for navigation difficulties.

In collaboration with Professor Neil Burgess at University College London (UCL) in the UK, a team at Cambridge led by Dennis Chan developed and trialed a VR navigation test in patients at risk of developing dementia.

In the test, a patient dons a VR headset and undertakes a test of navigation while walking within a simulated environment.

Successful completion of the task requires intact functioning of the entorhinal cortex, so Chan's team hypothesised that patients with early Alzheimer's disease would be disproportionately affected on the test.

The study, published in the journal Brain, recruited 45 patients with mild cognitive impairment (MCI).

Patients with MCI typically exhibit memory impairment, but while MCI can indicate early Alzheimer's, it can also be caused by other conditions such as anxiety and even normal ageing.

Establishing the cause of MCI is crucial for determining whether affected individuals are at risk of developing dementia in the future.

The researchers took samples of cerebrospinal fluid (CSF) to look for biomarkers of underlying Alzheimer's disease in their MCI patients, with 12 testing positive.

They also recruited 41 age-matched healthy controls for comparison.

All of the patients with MCI performed worse on the navigation task than the healthy controls.

MCI patients with positive CSF markers -- indicating the presence of Alzheimer's disease, thus placing them at risk of developing dementia -- performed worse than those with negative CSF markers at low risk of future dementia.

The VR navigation task was better at differentiating between these low and high-risk MCI patients than a battery of currently-used tests considered to be the gold standard for the diagnosis of early Alzheimer's.

"These results suggest a VR test of navigation may be better at identifying early Alzheimer's disease than tests we use at present in the clinic and in research studies," said Chan.

VR could also help clinical trials of future drugs aimed at slowing down, or even halting, a progression of Alzheimer's disease, researchers said.

Currently, the first stage of drug trials involves testing in animals, typically mouse models of the disease.

"The brain cells underpinning navigation are similar in rodents and humans, so testing navigation may allow us to overcome this roadblock in Alzheimer's drug trials and help translate basic science discoveries into clinical use," said Chan.

"We've wanted to do this for years, but it's only now that VR technology has evolved to the point that we can readily undertake this research in patients," he said.

Chan believes technology could play a crucial role in diagnosing and monitoring Alzheimer's disease.

He is working with Professor Cecilia Mascolo at Cambridge to develop apps for detecting the disease and monitoring its progression.

These apps would run on smartphones and smartwatches, researchers said.

As well as looking for changes in how we navigate, the apps will track changes in other everyday activities such as sleep and communication, they said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
July 8,2020

Probiotics that broaden the mix of helpful bacteria in the gut may help to ease depression, say researchers.

Foods that broaden the profile of helpful bacteria in the gut are collectively known as probiotics. These "good bacteria" can be taken as supplements, or found naturally in yoghurts or fermented foods.

For the findings, the research team from the University of Brighton in the UK searched for relevant studies published in English between 2003 and 2019, which looked at the potential therapeutic contribution of pre-and probiotics in adults with depression and/or anxiety disorders.

Out of an initial haul of 71 studies, just seven met all the criteria for inclusion. All 7 investigated at least one probiotic strain; four looked at the effect of combinations of multiple strains.In all, 12 probiotic strains featured in the selected studies, primarily Lactobacillus acidophilus, Lactobacillus casei, and Bifidobacterium bifidium.

One study looked at combined pre-probiotic treatment, while one looked at prebiotic therapy by itself. The studies varied considerably in their design, methods used, and clinical considerations, but all of them concluded that probiotic supplements either alone or in combination with prebiotics may be linked to measurable reductions in depression.

And every study showed a significant fall or improvement in anxiety symptoms and clinically relevant changes in biochemical measures of anxiety or depression with probiotic or combined pre-probiotic use.

Of the 12 different probiotics investigated, 11 were potentially useful, the findings showed.'Probiotics may help reduce the production of inflammatory chemicals, such as cytokines, as is the case in inflammatory bowel disease, the researchers suggested.

"They may help direct the action of tryptophan, a chemical thought to be important in the gut-brain axis in psychiatric disorders," they added.

In this way, with a better understanding of the mechanisms, probiotics may prove to be a useful tool across a wide range of conditions," the authors wrote.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 20,2020

The World Health Organisation has warned that the COVID-19 pandemic is entering a "new and dangerous" phase. Thursday saw the most cases in a single day reported to the WHO.

Tedros Adhanom Ghebreyesus said the day had seen 150,000 new cases with half of those coming from the Americas and large numbers also from the Middle East and South Asia, the BBC reported.

He said the virus was still spreading fast and the pandemic accelerating.

He acknowledged people might be fed up with self-isolating and countries were eager to open their economies but he said that now was a time for extreme vigilance.

Maria van Kerkhove, technical lead of the WHO's COVID-19 response, told a press conference the pandemic is "accelerating in many parts of the world".

"While we have seen countries have some success in suppressing transmission and bringing transition down to a low level, every country must remain ready," she said.

Mike Ryan, the head of the WHO's Health Emergencies Programme, said that some countries had managed to flatten the peak of infections without bringing them down to a very low level.

"You can see a situation in some countries where they could get a second peak now, because the disease has not been brought under control," he said.

"The disease will then go away and reduce to a low level, and they could then get a second wave again in the autumn or later in the year."

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
July 2,2020

London, Jul 2: The World Health Organisation says smoking is linked to a higher risk of severe illness and death from the coronavirus in hospitalised patients, although it was unable to specify exactly how much greater those risks might be.

In a scientific brief published this week, the U.N. health agency reviewed 34 published studies on the association between smoking and Covid-19, including the probability of infection, hospitalisation, severity of disease and death.

WHO noted that smokers represent up to 18% of hospitalised coronavirus patients and that there appeared to be a significant link between whether or not patients smoked and the severity of disease they suffered, the type of hospital interventions required and patients' risk of dying.

In April, French researchers released a small study suggesting smokers were at less risk of catching Covid-19 and planned to test nicotine patches on patients and health workers — but their findings were questioned by many scientists at the time who cited the lack of definitive data.

WHO says "the available evidence suggests that smoking is associated with increased severity of disease and death in hospitalized Covid-19 patients. It recommends that smokers quit.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.